In a phase 3 trial published Oct. 24, 2026, in the New England Journal of Medicine, adding tarlatamab to durvalumab maintenance extended median survival in extensive-stage small-cell lung cancer to 21.1 months vs. 12.7 months with durvalumab alone.
In a phase 3 trial published Oct. 25, 2026, in NEJM, people with PD-L1-negative advanced lung cancer went a median 15.0 months without progression on sacituzumab tirumotecan plus pembrolizumab vs. 5.7 months on chemotherapy plus pembrolizumab.
In a phase 3 trial published Oct. 26, 2026, in The Lancet, people with EGFR lung cancer that grew on EGFR pills went a median 8.3 months without progression on ruzaltatug rezetecan, vs. 5.4 months on chemotherapy, with similar rates…
In the NeoCOAST-2 trial, published Oct. 25, 2026, in Nature, people with operable lung cancer whose tumor DNA disappeared from the blood during treatment before surgery had much longer event-free survival (hazard ratio 0.22).
In the phase 2 MDT-BRIDGE trial, published Oct. 26, 2026, in Nature Medicine, 142 people with resectable or borderline lung cancer got durvalumab plus chemotherapy before surgery; 74.6% had their tumor removed and 92.3% received surgery or curative radiation.
In a phase 3 trial published Oct. 28, 2026, in the Journal of Clinical Oncology, adding pembrolizumab to focused radiation for early lung cancer that wasn't operated on did not delay recurrence and caused more serious side effects. The trial…
In a phase 3 trial published Oct. 26, 2026, in The Lancet, people with EGFR lung cancer that had grown on third-generation EGFR pills went a median 11.1 months without progression on iza-bren, vs. 5.7 months on chemotherapy. Serious side…
In a phase 3 trial published Oct. 25, 2026, in the New England Journal of Medicine, divarasib, a new KRAS G12C pill, extended median survival to 17.7 months vs. 12.0 months with sotorasib or adagrasib in previously treated lung cancer,…
In a phase 3 trial published Oct. 26, 2026, in the Journal of Clinical Oncology, people with EGFR lung cancer that escaped EGFR pills through MET amplification went a median 6.2 months without progression on dalmelitinib plus aumolertinib, vs. 4.4…